Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. A four-month FDA delay prompted a cash-strapped biotech company to shutter.
The White House’s proposed NIH cuts are drawing bipartisan backlash. Peptide hype is outpacing evidence.
And more! The need-to-know this morning Neurocrine Biosciences said this morning  that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome for $2.9 billion.
Neurocrine is paying $53 a share for Soleno, a 34% premium to its closing price on Thursday. A four-month FDA delay derailed a small biotech.
Is it a sign of the times? FDA delays can happen.
For large drugmakers, they can be frustrating; for small drugmakers, they can be existential. Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 06 Apr 2026.
The item focuses on STAT+: Stealth biotech Stipple bets on secretive ADCs.
Review the original article for the full source wording and details.